
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a promising biotechnology company with a strong pipeline and unique Enhanced Delivery Oligonucleotide platform. Their ability to target a broad range of tissues and organs, coupled with positive preclinical studies, puts them in a strong position for success. However, potential commercial and competitive challenges should be closely monitored.
Bears say
PepGen is a clinical-stage biotechnology company with a negative outlook due to its early-stage pipeline, complicated top-line results for its key drug candidate PGN-EDODM1, and uncertainty around its ability to gain approval and traction in the market. Additionally, the company's financials show a negative GAAP EPS and cash runway concerns based on its current operating plan. With a lowered target price of $5 (from $9) and questionable data from its FREEDOM-2 study, PepGen's stock may be a risky investment at this time.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares